Gut Microbiome Analysis in Neuromyelitis Optica Reveals Overabundance of Clostridium Perfringens

Bruce A. C. Cree, MD, PhD, MAS,1
Collin M. Spencer, BS,1,2
Michel Varrin-Doyer, PhD,1,2
Sergio E. Baranzini, PhD,1 and
Scott S. Zamvil, MD, PhD1,2

T cells from neuromyelitis optica (NMO) patients, which recognize the immunodominant epitope of aquaporin-4, exhibit Th17 polarization and cross-react with a homologous sequence of a Clostridium perfringens adenosine triphosphate-binding cassette transporter. Therefore, this commensal microbe might participate in NMO pathogenesis. We examined the gut microbiome by PhyloChip G3 from 16 NMO patients, 16 healthy controls (HC), and 16 multiple sclerosis patients. A significant difference in the abundance of several microbial communities was observed between NMO and HC (Adonis test, p = 0.001). Strikingly, C. perfringens was overrepresented in NMO (p = 5.24 × 10−3). These observations support a potential role for C. perfringens in NMO pathogenesis.

ANN NEUROL 2016;80:443–447

Neuromyelitis optica (NMO) is a central nervous system (CNS) autoimmune disease associated with a T-cell–dependent humoral response to the water channel, aquaporin-4 (AQP4).1,2 Previously, we observed that T cells from NMO patients proliferate more vigorously in response to AQP4 than T cells from healthy controls (HC).3 In NMO, T-cell recognition of the immunodominant determinant peptide (p) 63–76 was associated with Th17 polarization. We also discovered that AQP4 p63–76 contains a 10-amino-acid sequence, 66–75, that shares 90% homology with amino acid sequence 207–216 within an adenosine triphosphate-binding cassette transporter permease (ABC-TP) of Clostridium perfringens, a ubiquitous anaerobic gram-positive bacterium found in human commensal gut flora. T cells from NMO patients proliferated to the C. perfringens ABC-TP p207–216, and exhibited cross-reactivity with AQP4. These results suggested a possible link between C. perfringens and NMO pathogenesis.

Dysbiosis in gastrointestinal microbiota influences proinflammatory T-cell differentiation and can promote organ-specific autoimmunity.4 Clostridium species in human gut can influence the balance between Th17 and regulatory T cells (Treg).5 These observations, when taken together with our previous studies showing proinflammatory T-cell polarization and cross-reactivity between AQP4 and ABC-TP in NMO, highlighted the need to evaluate the proposed connection between C. perfringens and NMO pathogenesis.

To our knowledge, our findings in this report represent the first analysis of the gut microbiota in NMO.

Subjects and Methods

We examined stool samples obtained from 16 NMO patients (all AQP4 seropositive, Mayo Clinic Laboratory) and 16 unaffected controls by DNA hybridization using the PhyloChip G3. The G3 PhyloChip uses >1.1 million probes to target the entire 16S rRNA and can identify >60,000 taxa. Based upon other microbiome studies using the PhyloChip platform,6–9 16 individuals/group provided 90% power to detect an ω2 = 0.056,10 an effect size comparable to differences observed with diet.11 Unaffected NMO-household controls, when available, were used as the reference group to reduce variation related to diet. To further control for diet, subjects were asked to complete a validated food frequency questionnaire.12,13 Analysis of variance (ANOVA) was used to compare the mean values of dietary factors as well as age, height, weight, and body mass index (BMI) across the 3 groups (HC, NMO, and multiple sclerosis [MS]). Differences were considered significant if the F test yielded a p value of <0.05. Post hoc tests were used to assess pairwise comparisons for variables that differed among the groups. Most NMO patients were treated with immunotherapy (8 rituximab, 6 mycophenolate mofetil, 1 azathioprine, 1 untreated). Therefore, we included 16 MS subjects (5 treated with rituximab) as additional controls. This study received University of California, San Francisco Institutional Review Board approval.

DNA was extracted using MoBio PowerMag Soil DNA Isolation Kit as per the vendor’s protocol. DNA isolates ranged from the 1Department of Neurology, and 2Program in Immunology, University of California, San Francisco, San Francisco, CA.

Address correspondence to Dr Zamvil, Department of Neurology and Program in Immunology, University of California, San Francisco, 675 Nelson Raing Lane, NS-215A, San Francisco, CA 94158. E-mail: zamvil@ucsf.neuroimmunol.org

Current address for Dr Varrin-Doyer: Novartis AG, Basel, Switzerland.

Additional supporting information can be found in the online version of this article.

Received Feb 16, 2016, and in revised form Jun 27, 2016. Accepted for publication Jun 28, 2016.

View this article online at wileyonlinelibrary.com. DOI: 10.1002/ana.24718

in concentrations of 3 to 80 ng/µl. The bacterial 16S rRNA gene was amplified using the degenerate forward primer 27F: 5′-AGRGTTTGATCMTGGCTCAG-3′ and the non-degenerate reverse primer 1492R: 5′-GGTTACCTTGTTACGACTT-3′. Thirty-five cycles of bacterial 16S rRNA gene polymerase chain reaction (PCR) amplification were performed. Amplicons were concentrated using a solid-phase reversible immobilization method for the purification of PCR products and quantified by electrophoresis using an Agilent Technologies (Santa Clara, CA) 2100 Bioanalyzer. PhyloChip Control Mix was added to each amplified product. Bacterial 16S rRNA gene amplicons were fragmented, biotin labeled, and hybridized to the PhyloChip Array, version G3. Arrays were then washed, stained, and scanned using a GeneArray scanner (Affymetrix, Santa Clara, CA). Each scan was captured using standard Affymetrix software (GeneChip Microarray Analysis Suite).

The Adonis test (a randomization/Monte Carlo permutation test) was utilized to test for significant relationships between variation in bacterial community composition and discrete categorical or continuous variables measured in this study. ANOVA was used to test for significant taxonomic differences across HC, NMO, and MS.

Results

The clinical features of the patient and control groups are presented in Supplementary Table 1. Study subjects completed a dietary questionnaire (Block Dietary Data Systems, nutritionquest.com) that provided information regarding 73 nutrients as well as age, height, weight, and BMI (Supplementary Table 2). Nutritional intake between the 3 groups was remarkably similar. Only 4 dietary variables differed between the groups: alpha-carotene, beta-carotene, lutein-zeaxanthin, and phylloquinone (vitamin K1). NMO did not differ from HC on any nutritional or physical variable. For alpha-carotene, beta-carotene, and lutein-zeaxanthin, MS differed from both HC and NMO. Phylloquine (vitamin K1) in MS differed from NMO; however, MS did not differ from HC.

PhyloChip detected 2,621 operational taxonomic units (OTUs) in at least 1 sample. NMO and HC sample classes significantly explained variation in bacterial community composition based on a Weighted UniFrac matrix (Adonis test, p = 0.001).14 Principal component analysis was used to illustrate this finding; Figure 1A illustrates spatial separation of NMO and HC microbiomes indicating compositional differences between these bacterial communities. A total of 829 OTUs differed in relative abundance (uncorrected p < 0.05; Fig 2A). Forty-two retained statistical significance following Bonferroni correction for multiple comparisons (the cutoff for statistical significance following multiple comparison correction is p < 1.91 x 10^-5 = 0.05/2,621; Supplementary Table 3, Fig 2B).

Fifteen of 16 NMO patients were treated with immune suppressant medications that hypothetically could alter the gut microbiota (rituximab [n = 8], mycophenolate mofetil [n = 6], azathioprine [n = 1]).15 Therefore, we examined stool samples from 16 MS patients, 5 of whom were treated with rituximab, as an additional control. A total of 277 OTUs exhibited differential abundance between MS and HC (p < 0.05, unadjusted for multiple comparisons). Figure 2 illustrates the impact of correcting for multiple comparisons. Without correction, many species appear to have differential abundance in both MS and NMO. Following Bonferroni correction, no species were
associated with MS compared to HC. Differences in the gut microbiota between rituximab-treated MS and NMO patients were also identified, implying that these differences could not be attributed entirely to rituximab treatment (see Fig 1B).

Remarkably, *C. perfringens* was the second most statistically significantly enriched taxon in NMO patients compared with HC (*p* = 5.24 × 10⁻²⁸; see Supplementary Table 3). *C. perfringens* also was overrepresented in MS samples, albeit with marginal statistical significance, and did not survive statistical correction for multiple comparisons. In a 3-way comparison, *C. perfringens* was overabundant comparing NMO to HC (*p* < 0.0001) and NMO to MS (*p* = 0.004) but was not different comparing MS to HC (*p* = not significant; Fig 3). *C. perfringens* remained significantly associated with NMO for the comparison of the subgroup of 8 NMO rituximab-treated and 5 MS rituximab-treated subjects (*p* = 0.049). Within MS samples, rituximab treatment did not influence *C. perfringens* abundance (*p* = 0.507). Similarly, rituximab treatment did not influence *C. perfringens* abundance among NMO subjects (*p* = 0.464).

**Discussion**

Our previous investigation discovered striking homology between the immunodominant T-cell epitope of AQP4 in NMO and a sequence of an ABC-TP of *C. perfringens*. AQP4-specific T cells exhibited Th17 polarization and cross-reacted with the corresponding ABC-TP peptide. Both commensal *Clostridium* species in humans and the phylogenetically related segmented filamentous bacteria (SFB) in mice can influence the balance between Th17 and Treg,¹⁷ T-cell subsets that are reciprocally regulated.¹⁷ Specifically, colonization of the terminal ileum of germ-free mice with a single commensal microbe, SFB, promoted Th17 differentiation and resulted in the induction of experimental autoimmune encephalomyelitis.¹⁸ Further, colonization of germ-free mice
with one fraction of human fecal material containing multiple Clostridium strains promoted development of Foxp3⁺ Treg, whereas colonization with another fraction expanded Th17 cells. Thus, we hypothesized that C. perfringens might have a dual role in NMO pathogenesis, serving both as a molecular mimic and its own proinflammatory polarizing adjuvant. In this first study of the microbiome in NMO, we found that several OTUs are differentially represented in NMO compared to HC. Notably, C. perfringens is significantly enriched in relative abundance in the gut microbiota of NMO. This observation provides evidence supporting the potential role of C. perfringens in NMO pathogenesis.

There are several implications from our findings. First, our data provide a potential link between the gut microbiota and NMO, an acquired antigen-specific neurological disease. Second, overrepresentation of C. perfringens in the gut could be one factor contributing to immune dysregulation and NMO susceptibility. Third, it is possible that C. perfringens might participate in more than one CNS autoimmune disease. In this regard, one year after we identified the potential link between C. perfringens and NMO, C. perfringens was implicated in MS pathogenesis. Another study found that Clostridium species within clusters XIVa and IV, which do not contain C. perfringens (a member of cluster I), are reduced in relapsing–remitting MS patients. In our data set, C. perfringens was also increased in MS samples; however, its association with MS, unlike NMO, did not withstand statistical correction. Although we have drawn attention largely to C. perfringens, other bacterial community members (e.g., Fibrobacteres) appear to be overrepresented in NMO gut microbiota (see Supplementary Table 3). Thus, it is possible that other bacterial species may also influence immune function in these patients.

This initial study is limited by a small sample size, and it was designed primarily to investigate feasibility rather than to provide a definitive answer regarding potential differences in the gut microbiome of NMO patients. Because of the potential impact of immunosuppressive medications on the gut microbiota, future studies will focus on stool samples obtained from untreated NMO patients. Due to the relatively rapid diagnosis based on anti-AQP4 serology, most NMO patients are started on an immunosuppressive medication shortly following diagnosis, creating logistic challenges for acquisition of treatment-naive samples. In this data set, we cannot prove that the differences observed in the microbiome between NMO and HC are not influenced by treatment. Nonetheless, restricting the comparison of rituximab-treated NMO to rituximab-treated MS patients showed that C. perfringens abundance was significantly elevated in NMO. Therefore, immunosuppressive treatments alone cannot account for the differences between NMO and HC because the microbiota of MS and NMO patients treated in a similar manner were distinct. Furthermore, the case–control study design can identify associations but does not permit determination of causality. Additional evidence of a direct role might be gained from animal experimentation by evaluating immune reactivity to AQP4 following colonization of germ-free mice with fecal material from NMO patients. Despite these limitations, our observation of a highly significant overrepresentation of C. perfringens within the gut microbiota of NMO subjects warrants further investigation of the potential role of this organism in immune dysregulation in NMO.

Acknowledgment

This work was supported by grants to S.S.Z. from the Guthy-Jackson Charitable Foundation and the National Multiple Sclerosis Society (RG 4768). S.E.B. received support from the Valhalla Foundation and S.S.Z. was also supported by the Alexander M. and June L. Maisin Foundation of the Jewish Community Federation and Endowment Fund.

We thank Drs S. V. Lynch, G. R. Cutter, and M. R. Yeaman for helpful discussion and review of the manuscript; and the patients and their families for their contributions to this project.

Author Contributions

B.A.C.C., C.M.S., M.V-D., and S.S.Z contributed to study concept and design. B.A.C.C., C.M.S., S.E.B., and S.S.Z. contributed to data acquisition and analysis. B.A.C.C., C.M.S., and S.S.Z contributed to drafting the manuscript or figures.

Potential Conflicts of Interest

S.S.Z. has received personal compensation for consulting from Roche (rituximab is a product of Genentech, a Roche company).

References


